# A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

> **NCT04008355** · PHASE2 · COMPLETED · sponsor: **AlzProtect SAS** · enrollment: 36 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** AZP2006 oral solution
- **DRUG:** Placebo oral solution

## Key facts

- **NCT ID:** NCT04008355
- **Lead sponsor:** AlzProtect SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-22
- **Primary completion:** 2022-07-18
- **Final completion:** 2024-09-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008355, "A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04008355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*